Zobrazeno 1 - 10
of 112
pro vyhledávání: '"Ronan, Flippot"'
Autor:
Loubna Omri, Marie Naigeon, Ronan Flippot, Javier Gavira-Díaz, Jesus Poveda-Ferriols, Dan Nguyen, Chaimae Abdi, Alvaro Arroyo-Salgado, Nathalie Chaput, Guillermo de Velasco, Laurence Albigès, Lucía Carril-Ajuria
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 5, Iss 6, Pp 1199-1222 (2024)
Immune checkpoint inhibitors (ICI)-based combinations have become the standard first-line treatment for advanced clear cell renal cell carcinoma (ccRCC). Despite significant improvements in survival and the achievement of sustained long-term response
Externí odkaz:
https://doaj.org/article/cbe52b195cea4f959c15c477362b78ef
Autor:
Nicolas Jacquin, Ronan Flippot, Julien Masliah-Planchon, Guillaume Grisay, Riwan Brillet, Célia Dupain, Maud Kamal, Isabelle Guillou, Nadège Gruel, Nicolas Servant, Pierre Gestraud, Jennifer Wong, Vincent Cockenpot, Andreia Goncalves, Janick Selves, Hélène Blons, Etienne Rouleau, Olivier Delattre, Claire Gervais, Christophe Le Tourneau, Ivan Bièche, Yves Allory, Laurence Albigès, Sarah Watson
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-6 (2024)
Abstract Metastatic carcinoma of presumed renal origin (rCUP) has recently emerged as a new entity within the heterogeneous entity of Cancers of Unknown Primary (CUP) but their biological features and optimal therapeutic management remain unknown. We
Externí odkaz:
https://doaj.org/article/8884285fa1394307af735d86552e3c29
Autor:
Jean-Yves Scoazec, Francois-Xavier Danlos, Laurence Albiges, Bernard Escudier, Ronan Flippot, Lydie Cassard, Nathalie Chaput, Natacha Naoun, Marie Naigeon, Jean-Mehdi Jouniaux, Lisa Boselli, Lucia Carril-Ajuria, Marcus Teixeira, Macarena Rey-Cardenas, Larissa Rainho
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)
Immunotherapy profoundly changed the landscape of cancer therapy by providing long-lasting responses in subsets of patients and is now the standard of care in several solid tumor types. However, immunotherapy activity beyond conventional immune check
Externí odkaz:
https://doaj.org/article/4d45ec442ac34e56a8ca723b8b181cf8
Autor:
Laurence Albiges, Bernard Escudier, Gwenaelle Gravis, Ronan Flippot, Alain Ravaud, Maxime Meylan, Nathalie Rioux-Leclercq, Marine Gross-Goupil, Gaëlle Fromont, Christophe Passot, Lionnel Geoffrois, Fréderic Rolland, Manon de Vries-Brilland, Jonathan Dauvé, Elena Spirina-Menand, Christine Chevreau, Ellen Blanc, Félix Lefort, Sylvie Negrier
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 11 (2023)
Background Papillary renal cell carcinoma (pRCC) is the most common non-clear cell RCC, and associated with poor outcomes in the metastatic setting. In this study, we aimed to comprehensively evaluate the immune tumor microenvironment (TME), largely
Externí odkaz:
https://doaj.org/article/e2ce2468aad14a5187730a92accb65ce
Autor:
Emeline Colomba, Carolina Alves Costa Silva, Gwénaël Le Teuff, Jamie Elmawieh, Daniel Afonso, Axelle Benchimol‐Zouari, Annalisa Guida, Lisa Derosa, Ronan Flippot, Bruno Raynard, Bernard Escudier, François Bidault, Laurence Albiges
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 13, Iss 5, Pp 2405-2416 (2022)
Abstract Background Cabozantinib, a standard of care metastatic renal cell carcinoma (mRCC), may be associated with weight and muscle loss. These effects of new generation VEGFR tyrosine kinase inhibitor on muscle mass loss are poorly described. Meth
Externí odkaz:
https://doaj.org/article/9c6e69245d384a6088532908f44f179b
Autor:
Ziad Bakouny, David A. Braun, Sachet A. Shukla, Wenting Pan, Xin Gao, Yue Hou, Abdallah Flaifel, Stephen Tang, Alice Bosma-Moody, Meng Xiao He, Natalie Vokes, Jackson Nyman, Wanling Xie, Amin H. Nassar, Sarah Abou Alaiwi, Ronan Flippot, Gabrielle Bouchard, John A. Steinharter, Pier Vitale Nuzzo, Miriam Ficial, Miriam Sant’Angelo, Juliet Forman, Jacob E. Berchuck, Shaan Dudani, Kevin Bi, Jihye Park, Sabrina Camp, Maura Sticco-Ivins, Laure Hirsch, Sylvan C. Baca, Megan Wind-Rotolo, Petra Ross-Macdonald, Maxine Sun, Gwo-Shu Mary Lee, Steven L. Chang, Xiao X. Wei, Bradley A. McGregor, Lauren C. Harshman, Giannicola Genovese, Leigh Ellis, Mark Pomerantz, Michelle S. Hirsch, Matthew L. Freedman, Michael B. Atkins, Catherine J. Wu, Thai H. Ho, W. Marston Linehan, David F. McDermott, Daniel Y. C. Heng, Srinivas R. Viswanathan, Sabina Signoretti, Eliezer M. Van Allen, Toni K. Choueiri
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
Sarcomatoid and rhabdoid tumours are highly aggressive forms of renal cell carcinoma that are also responsive to immunotherapy. In this study, the authors perform a comprehensive molecular characterization of these tumours discovering an enrichment o
Externí odkaz:
https://doaj.org/article/65b689f6ed0042b1ab0807dd0eb2f0de
Autor:
Pernelle Lavaud, Clément Dumont, Constance Thibault, Laurence Albiges, Giulia Baciarello, Emeline Colomba, Ronan Flippot, Alina Fuerea, Yohann Loriot, Karim Fizazi
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Until recently, continuing androgen deprivation therapy (ADT) and closely monitoring patients until evolution towards metastatic castration-resistant prostate cancer (CRPC) were recommended in men with non-metastatic CRPC (nmCRPC). Because delaying t
Externí odkaz:
https://doaj.org/article/631263ea1bcb47c7939c497907d7f7ae
Autor:
Xiao Wei, Marina D Kaymakcalan, Daniel Y C Heng, Wanling Xie, Sarah Abou Alaiwi, Amin H Nassar, Shaan Dudani, Dylan Martini, Ziad Bakouny, John A Steinharter, Pier Vitale Nuzzo, Ronan Flippot, Nieves Martinez-Chanza, Bradley A McGregor, Mehmet A Bilen, Lauren C Harshman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundImmune checkpoint inhibitors (ICI) induce a range of immune-related adverse events (irAEs) with various degrees of severity. While clinical experience with ICI retreatment following clinically significant irAEs is growing, the safety and ef
Externí odkaz:
https://doaj.org/article/cddad0a5c98242358042f98cc6c1686d
Autor:
Sarah Abou Alaiwi, Amin H Nassar, Pier Vitale Nuzzo, Ronan Flippot, Bradley A McGregor, Lauren C Harshman, Gregory R Pond, Catherine Curran, Kerry L Kilbridge, Xiao X Wei, Toni Choueiri
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundImmune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs). Although the incidence and prevalence of irAEs have been well characterized in the literature, less is known about the cumulative incidence rate
Externí odkaz:
https://doaj.org/article/f9a53e784a40492e874a776edb028735
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
The treatment landscape of metastatic renal cell carcinoma (mRCC) has been transformed with the advent of antiangiogenics, notably tyrosine kinase inhibitors (TKIs) targeting vascular endothelial growth factor receptor (VEGFR), and immune checkpoint
Externí odkaz:
https://doaj.org/article/52bd828340054438a6e4fb7c9a93f2d6